AYGEN, B. Et Al. 2018. Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies. Austin Pharmacology Pharmaceutics , vol.3, no.1 .

AYGEN, B., YILDIZ, O., GÖKAHMETOĞLU, S., & BALTACI, S., (2018). Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies. Austin Pharmacology Pharmaceutics , vol.3, no.1.

AYGEN, BİLGEHAN Et Al. "Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies," Austin Pharmacology Pharmaceutics , vol.3, no.1, 2018

AYGEN, BİLGEHAN Et Al. "Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies." Austin Pharmacology Pharmaceutics , vol.3, no.1, 2018

AYGEN, B. Et Al. (2018) . "Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies." Austin Pharmacology Pharmaceutics , vol.3, no.1.

@article{article, author={BİLGEHAN AYGEN Et Al. }, title={Sofosbuvir Plus Ledipasvir Treatment in Patients withHepatitis C Genotype 4d Infection who PreviouslyFailed to Achieve Sustained Virological Response withTelaprevir or Boceprevir Combination Therapies}, journal={Austin Pharmacology Pharmaceutics}, year=2018}